The Reply.
作者信息
McCullough Peter A
机构信息
Department of Internal Medicine, Baylor University Medical Center, Dallas, Tex; Baylor Heart and Vascular Institute, Dallas, Tex; Division of Cardiovascular Medicine, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, Tex.
出版信息
Am J Med. 2021 Mar;134(3):e222-e223. doi: 10.1016/j.amjmed.2020.10.036.
Abstract
摘要
相似文献
1
The Reply.回复。
Am J Med. 2021 Mar;134(3):e222-e223. doi: 10.1016/j.amjmed.2020.10.036.
2
The Reply.回复。
Am J Med. 2021 Apr;134(4):e298. doi: 10.1016/j.amjmed.2020.11.028.
3
The Reply.回复。
Am J Med. 2021 May;134(5):e346-e347. doi: 10.1016/j.amjmed.2021.01.013.
4
The Reply.回复。
Am J Med. 2021 May;134(5):e343-e344. doi: 10.1016/j.amjmed.2021.01.011.
5
Comments on the Pathophysiological Basis and Rationale for Early Treatment of COVID-19.关于2019冠状病毒病早期治疗的病理生理基础及理论依据的评论
Am J Med. 2021 May;134(5):e341-e342. doi: 10.1016/j.amjmed.2021.01.004.
6
Engaging and Empowering the Front Lines During the COVID-19 Outpatient Practice Reactivation.在新冠疫情门诊恢复运营期间调动一线人员积极性并赋予其权力
Mayo Clin Proc. 2020 Sep;95(9S):S47-S51. doi: 10.1016/j.mayocp.2020.06.040. Epub 2020 Jun 30.
7
Risk of COVID-19 Transmission from Infected Outpatients to Healthcare Workers in an Outpatient Clinic.感染门诊患者对门诊医护人员发生 COVID-19 传播的风险。
J Korean Med Sci. 2020 Dec 28;35(50):e431. doi: 10.3346/jkms.2020.35.e431.
8
Outpatient Evaluation and Management of COVID-19.COVID-19 的门诊评估与管理。
Ann Intern Med. 2022 Apr;175(4):590-591. doi: 10.7326/M22-0403. Epub 2022 Feb 15.
9
[Not Available].[无可用内容]
MMW Fortschr Med. 2022 Jan;164(1):24-26. doi: 10.1007/s15006-021-0542-z.
10
High prevalence of olfactory and taste disorder during SARS-CoV-2 infection in outpatients.门诊患者感染新型冠状病毒期间嗅觉和味觉障碍的高患病率。
J Med Virol. 2020 Nov;92(11):2310-2311. doi: 10.1002/jmv.25995. Epub 2020 May 17.
引用本文的文献
1
Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath.拉马曲班用于 COVID-19 的化学预防和治疗：大卫对战歌利亚。
Expert Opin Ther Targets. 2022 Jan;26(1):13-28. doi: 10.1080/14728222.2022.2031975. Epub 2022 Feb 22.
本文引用的文献
1
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).非那韦和对 SARS-CoV-2 感染（COVID-19）早期门诊治疗的需求。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.02017-20.
2
Favipiravir: A new and emerging antiviral option in COVID-19.法匹拉韦：COVID-19 中一种新兴的抗病毒新选择。
Med J Armed Forces India. 2020 Oct;76(4):370-376. doi: 10.1016/j.mjafi.2020.08.004. Epub 2020 Sep 2.
3
Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection.SARS-CoV-2（COVID-19）感染早期门诊治疗的病理生理基础和原理。
Am J Med. 2021 Jan;134(1):16-22. doi: 10.1016/j.amjmed.2020.07.003. Epub 2020 Aug 7.
4
Prostaglandin D as a mediator of lymphopenia and a therapeutic target in COVID-19 disease.前列腺素 D 作为 COVID-19 疾病中淋巴细胞减少症的介质和治疗靶点。
Med Hypotheses. 2020 Oct;143:110122. doi: 10.1016/j.mehy.2020.110122. Epub 2020 Jul 21.
5
Current Overview on Hypercoagulability in COVID-19.新型冠状病毒肺炎患者高凝状态的研究现状。
Am J Cardiovasc Drugs. 2020 Oct;20(5):393-403. doi: 10.1007/s40256-020-00431-z.
Zotero 插件